Crisaborole ointment 2% (EucrisaTM) is a new anti-inflammatory phosphodiesterase 4 (PDE4) inhibitor that is approved in the United States for the topical treatment of mild to moderate atopic dermatitis in children aged 2 years. Topical therapy with crisaborole ointment decreased disease severity and pruritus severity by 2% in two short-term (28 days), similarly planned, multicentre, phase III trials in this patient group, with the benefit established early and persisted over the course of treatment. Other atopic dermatitis symptoms (erythema, exudation, excoriation, induration/papulation, and lichenification) improved as well.
Crisaborole ointment 2% was usually well tolerated in short-term tests and its excellent safety profile was maintained in a multicenter, extension study over the longer-term (up to 52 weeks). The majority of treatment-emergent adverse events (TEAEs) were mild to moderate in intensity and were not thought to be connected to the study drug. Furthermore, application-site discomfort was uncommon following short- and long-term topical treatment with crisaborole ointment 2%.
To summarize, crisaborole ointment 2% is an effective and generally well-tolerated new topical option for the treatment of mild to moderate atopic dermatitis in children aged 2 years and older, with the potential to effectively treat this patient population over the long term without the safety concerns associated with other topical anti-inflammatory agents.
Reference:link.springer.com/article/10.1007/s40257-017-0327-4
